Abstract:Overview: Immunotherapy has revolutionized cancer treatment. However, existing immune checkpoint inhibitors (CPI) yield low response rates in most cancers, highlighting the need for new therapeutic options. Traditional immune-oncology (IO) target discovery relies on preclinical models, which struggle to recapitulate human tumor complexity, limiting translation potential. Attention is thus directed at harnessing multimodal patient molecular data with modern machine learning (ML) techniques to identify new IO targets which may have higher clinical viability. Approach: We posed IO target discovery as a binary classification task, training ML systems on known candidate drug targets that have progressed to stage I or higher clinical trials. We constructed a rich knowledge graph database to support model development. Graph nodes (n=11,919) comprised genes with edges linking genes involved in n=99,275 protein-protein interactions (PPIs; PMID: 28936969). Genes were labelled with n=6,387 gene-disease associations alongside bulk exome and transcriptome (RNAseq) features from n=1,317 CPI-treated patients (PMID: 33508232). We considered the role of different immune subsets by incorporating cell type-specific PPIs from single cell RNAseq atlases of n=350 samples (PMID: 31786210). To capture how antigen processing affects immunotherapy response, we also examined the immunopeptidome of n=60 patients (PMID: 30556813). Causal data on immune responses to genetic perturbation stemmed from n=7 publicly available CRISPR tumor-T cell co-cultures and n=15,442 SNP-phenotype links. Lastly, we used interpretability analysis to understand drivers of model predictions and elucidate critical genes that influence multiple IO target pathways. Results: Firstly, we developed an ensemble ML approach which achieved test ROC-AUC>0.75. Next, we used a graph-based ML framework which yielded superior performance (test ROC-AUC>0.90). Orthogonal validation confirmed these models can discriminate known targets by trial phase (p<0.001), predict patient response in new CPI trials (p<0.05), and identify genes that rank highly in unseen genome-wide CRISPR screens. Targets from both methods have entered experimental validation in patient-derived explants and organoid-immune co-cultures. Already, we have identified 2 novel targets predicted to relate to macrophage activity. Early data suggest that perturbing them leads to macrophage repolarization. Further validation experiments are ongoing. Conclusions: We will reveal candidate targets, showing that our method is effective at uncovering new IO targets and can identify critical nodes in biological networks that might be attractive hits. In addition, deciphering data types that drive model predictions provides a broader immunobiological understanding of anti-tumor immune responses. Thus, our results endorse using ML and multimodal data for novel IO target discovery. Citation Format: Marcellus Augustine, Nuno Rocha Nene, Krupa Thakkar, Danwen Qian, Evelyn Fitzsimons, Benjamin S. Simpson, Chris Watkins, Charles Swanton, Kevin Litchfield. Identifying new immunotherapy targets using machine learning and ex vivo validation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5887.

Explainable Machine Learning for Profiling the Immunological Synapse and Functional Characterization of Therapeutic Antibodies.

AI driven B-cell Immunotherapy Design

Using the antibody-antigen binding interface to train image-based deep neural networks for antibody-epitope classification

Abstract 1045: A freely expandable 20-plex immuno-oncology antibody core panel for spatial biology experiments on human FFPE cancer sections: REAplex IO Core for MICS technology

Data-driven discovery of innate immunomodulators via machine learning-guided high throughput screening

Computational immune synapse analysis reveals T-cell interactions in distinct tumor microenvironments

Expert-Level Immunofixation Electrophoresis Image Recognition Based on Explainable and Generalizable Deep Learning

Leveraging Artificial Intelligence to Expedite Antibody Design and Enhance Antibody–Antigen Interactions

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies

Deep Learning-Inferred Multiplex ImmunoFluorescence for IHC Image Quantification

Abstract 3803: Spatial architecture of tumor and immune cell lineages in syngeneic mouse tumor tissues

ImmunoStruct: Integration of protein sequence, structure, and biochemical properties for immunogenicity prediction and interpretation

Imaged capillary isoelectric focusing associated with multivariate analysis: A powerful tool for quality control of therapeutic monoclonal antibodies

Predicting single-cell gene expression profiles of imaging flow cytometry data with machine learning

Functional and epitope specific monoclonal antibody discovery directly from immune sera using cryoEM

Abstract 6878: Images to insights: Transforming TME characterization into actionable spatial metrics with AI-powered multiplex immunofluorescence

Abstract 4169: A deep learning approach to guide acquisition region selection for imaging mass cytometry

Antibody Representation Learning for Drug Discovery

Abstract 5887: Identifying new immunotherapy targets using machine learning and ex vivo validation

Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery

Machine-designed biotherapeutics: opportunities, feasibility and advantages of deep learning in computational antibody discovery